The Insider David Schenkein Unloaded 23572 shares of Agios Pharmaceuticals, Inc. (AGIO); Lifetime Brands Has 0.97 Sentiment

Lifetime Brands, Inc. designs, sources, and sells branded kitchenware, tableware, and other products for use in the home in the United States and internationally. The company has market cap of $259.21 million. The firm operates through three divisions: U.S. It has a 16.57 P/E ratio. Wholesale, International, and Retail Direct.

Director David Schenkein of Agios Pharmaceuticals Inc, sold 23,572 of the stock exchange listed company shares having a value near $1,911,494 USD with an average of $81.1 per share. He also unloaded 99,428 shares with a market value $7,591,922 USD in the last 30 days. Due to the size of the stocks unloading there is little probability that it will remain hidden. David Schenkein right now possess 350,854 shares or 0.63% of Agios Pharmaceuticals Inc’s market cap.

Investors sentiment decreased to 1.21 in 2017 Q3. Its down 0.83, from 2.04 in 2017Q2. It fall, as 22 investors sold Agios Pharmaceuticals, Inc. shares while 44 reduced holdings. 29 funds opened positions while 51 raised stakes. 44.69 million shares or 0.07% less from 44.72 million shares in 2017Q2 were reported. Td Asset Management reported 33,800 shares. 27,850 are owned by Fernwood Invest Ltd. Vanguard Gp accumulated 3.29M shares or 0.01% of the stock. Utah Retirement has invested 0.01% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Macquarie Gru, Australia-based fund reported 3,675 shares. 16,650 were reported by Creative Planning. Qs Lc holds 0% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 2,800 shares. Capital Guardian Co stated it has 729,714 shares. Legal And General Public Ltd Com invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Oppenheimer Asset Mgmt holds 0% or 37 shares in its portfolio. 12,216 are held by Bnp Paribas Arbitrage Sa. Alkeon Cap Mgmt Lc has invested 0.23% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Mutual Of America Cap Ltd Limited Liability Company, New York-based fund reported 30,356 shares. 15,000 were reported by Rhenman Partners Asset Mngmt Ab. Capital Int reported 0.25% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals has $132 highest and $47 lowest target. $75.64’s average target is -6.17% below currents $80.61 stock price. Agios Pharmaceuticals had 41 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co with “Buy” on Tuesday, August 1. The stock has “Buy” rating by J.P. Morgan on Monday, September 18. JP Morgan upgraded Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) rating on Monday, June 13. JP Morgan has “Overweight” rating and $62 target. The company was maintained on Tuesday, August 8 by Oppenheimer. The company was maintained on Tuesday, August 8 by Cowen & Co. SunTrust maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) rating on Tuesday, October 3. SunTrust has “Buy” rating and $80.0 target. The firm has “Buy” rating given on Monday, June 13 by Canaccord Genuity. The firm earned “Outperform” rating on Thursday, January 21 by Credit Suisse. The company was maintained on Sunday, June 11 by Oppenheimer. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Buy” rating by Suntrust Robinson on Wednesday, May 18.

The stock increased 0.40% or $0.32 during the last trading session, reaching $80.61. About 644,570 shares traded or 15.19% up from the average. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 8.52% since January 31, 2017 and is uptrending. It has underperformed by 8.18% the S&P500.

Analysts await Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report earnings on February, 15. They expect $-1.65 earnings per share, down 23.13% or $0.31 from last year’s $-1.34 per share. After $-1.59 actual earnings per share reported by Agios Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 3.77% negative EPS growth.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $4.49 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Since August 1, 2017, it had 0 buys, and 18 insider sales for $21.70 million activity. Schenkein David P had sold 80,000 shares worth $5.61M. $732,900 worth of stock was sold by Biller Scott on Wednesday, October 4. $161,250 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was sold by Alenson Carman on Friday, January 12. The insider Cantley Lewis Clayton Jr. sold $284,380. Bowden Christopher sold 6,000 shares worth $390,000. 25,000 shares were sold by Hoerter Steven L., worth $1.87 million.

Petrus Trust Company Lta holds 2.08% of its portfolio in Lifetime Brands, Inc. for 480,000 shares. Pacific Ridge Capital Partners Llc owns 267,441 shares or 1.39% of their US portfolio. Moreover, Clark Estates Inc Ny has 0.55% invested in the company for 179,607 shares. The Tennessee-based Martin & Co Inc Tn has invested 0.43% in the stock. Olstein Capital Management L.P., a New York-based fund reported 144,263 shares.

It closed at $17.4 lastly. It is up 36.80% since January 31, 2017 and is uptrending. It has outperformed by 20.10% the S&P500.